Canada Markets close in 4 hrs 9 mins

DiaMedica Therapeutics Inc. (DMAC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.3900+0.0200 (+0.46%)
As of 10:56AM EDT. Market open.
Sign in to post a message.
  • s
    s
    Dmac great product. Amazing things in the works. Ten bagger. Ten bagger ten bagger
  • s
    s
    Here we go. Type 2 diabetes kidney disease. This is gonna be good
  • M
    Manny
    Diamedica’s DM199 will be the new standard of care of Acute Ischemic stroke.It decreases mortality rate of Acute Ischemic Stroke by 50%, increases number of patients with excellent outcome NIHSS 0-1 by 157%, decrease occurrence of severe recurrent stroke by 85%.Yet markcap us only 100M. This drug could help hundreds of thousands of lives yet the market didn’t noticed.
  • M
    Manny
    @diamedica #DM199 decreases mortality rate of Acute Ischemic Stroke by 50%, increases # of patient with excellent outcome NIHSS 0-1 by 85%, decrease occurrence of severe recurrent stroke by 85% yet no one noticed.
  • s
    s
    DM199 could/should also move kidney disease a quantum leap forward. Used in China and the East already. Their Post hoc data from stroke trial presented last call was remarkable.

    This is blockbuster for stroke and also blockbuster for kidney disease !!!!!!!
  • s
    s
    Hedge funds in.

    Multiple data and catalysts pending !!!

    Will be stock of year 2020 !!
  • M
    Manny
    DM199 will definitely benefit AIS patients who can’t have TPA and MT. That’s >80% of AIS patients. It reduces mortality of those patients into half. Remdesivir was approved yet it didn’t benefit mortality rate for Covid Patients only decrease their hospital stay. Management need to admit that their study design was flawed and proceed to phase 3 but this time excluding patients who receive TPA and MT. Their target population are the one who doesn’t qualify for both treatment yet most of the study subjects had those treatment. Really incompetent.
  • J
    June
    At this price it’s still way undervalued. Target price with the current data is $80-100. Once phase II result for CKD is out target price is $200-250.
  • A
    Anonymous
    are there buyout rumors circulating? trying to articulate the sudden move today.
  • T
    Tailspin
    DiaMedica - 7/19/18 False information showing up in the Media that Zack's has downgraded $DMCAF --- This is false --What actually happened was an error at Zack's and DMCAF was ACCIDENTALLY DELETED from their database. Zack's is working to correct the problem.
    Yesterday and today price has gone down which presents a buying opportunity --- IMO
  • A
    Anonymous
    Where is phase II data....???
  • E
    Elon
    DMAC is due for a $4.5m milestone payment from Ahon by the end of the summer (sep23) Earnings announcement with more granularity on CKD and stroke trials should all be within a month.
  • s
    s
    This medication is gonna be hot. Stroke trial data to be presented soon. Should be outstanding. Market cap will rise significantly. This to be quickly followed by two kidney trials. High hopes. Huuuuge returns !!!!!
  • J
    John
    John Mauldin’s Biotech company -- DiaMedica (TSXV:DMA; OTCQB:DMCAF)

    Compound is blood vessel opening, blood flow promoting substance used in many situations but especially those suffering a stroke. A total of 40 published clinical studies.

    Compound used in Asia coming from pig pancreases and urine from young humans at very high cost.

    Diamedica’s improved the compound with a synthetic version at a fraction of the cost.



    Mauldin Economics write-up https://tinyurl.com/yao9dl9d
    Shared with Dropbox
    Shared with Dropbox
    tinyurl.com
  • j
    jim
    KSSMDPhD's avatar
    KSS, MD, PhD
    @KSSMDPhD
    $DMCAF shares snappy with company disclosing $7.6M EOQ 31 Mar assets vs $1.5M prior quarter. Seismic upheaval in CVA SOC pending in a space where PTB have set bar very low. Only way to go is up, led by $DMCAF.
  • A
    Anonymous
    Did they say in earnings release that data from trial would be posted by now
  • R
    Robert
    I hope that the conference call is positive and possibly talk about the data from the phase 2 study
  • F
    Flóki
    To the moon in a few years?
  • Q
    Queen Bee
    DiaMedica Therapeutics Inc. (the “Company” and “DiaMedica”) (DMA.V) (DMCAF) announces the recent appointment of Harry Alcorn Jr. Pharm.D. as Chief Medical Officer where he will oversee global clinical development and regulatory initiatives for DiaMed
    DiaMedica Therapeutics Inc. (the “Company” and “DiaMedica”) (DMA.V) (DMCAF) announces the recent appointment of Harry Alcorn Jr. Pharm.D. as Chief Medical Officer where he will oversee global clinical development and regulatory initiatives for DiaMed
    finance.yahoo.com